- Home
- PKX vs RPRX Comparison
PKX vs RPRX Comparison
Compare PKX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKX
- RPRX
- Stock Information
- Founded
- PKX 1968
- RPRX 1996
- Country
- PKX South Korea
- RPRX United States
- Employees
- PKX N/A
- RPRX N/A
- Industry
- PKX Steel/Iron Ore
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- PKX Industrials
- RPRX Health Care
- Exchange
- PKX Nasdaq
- RPRX Nasdaq
- Market Cap
- PKX 13.7B
- RPRX 14.3B
- IPO Year
- PKX 1994
- RPRX 2020
- Fundamental
- Price
- PKX $45.64
- RPRX $32.88
- Analyst Decision
- PKX
- RPRX Strong Buy
- Analyst Count
- PKX 0
- RPRX 4
- Target Price
- PKX N/A
- RPRX $42.50
- AVG Volume (30 Days)
- PKX 193.2K
- RPRX 5.8M
- Earning Date
- PKX 07-24-2025
- RPRX 05-08-2025
- Dividend Yield
- PKX 2.33%
- RPRX 2.68%
- EPS Growth
- PKX N/A
- RPRX 37.60
- EPS
- PKX 7.09
- RPRX 2.45
- Revenue
- PKX $48,940,356,800.00
- RPRX $2,263,845,000.00
- Revenue This Year
- PKX $1.01
- RPRX $31.16
- Revenue Next Year
- PKX $4.02
- RPRX $6.37
- P/E Ratio
- PKX $25.02
- RPRX $13.41
- Revenue Growth
- PKX N/A
- RPRX 1.13
- 52 Week Low
- PKX $39.40
- RPRX $24.05
- 52 Week High
- PKX $74.01
- RPRX $34.32
- Technical
- Relative Strength Index (RSI)
- PKX 52.17
- RPRX 51.49
- Support Level
- PKX $42.35
- RPRX $32.15
- Resistance Level
- PKX $46.52
- RPRX $32.82
- Average True Range (ATR)
- PKX 0.73
- RPRX 0.72
- MACD
- PKX 0.20
- RPRX -0.07
- Stochastic Oscillator
- PKX 65.54
- RPRX 33.72
About PKX POSCO Holdings Inc.
POSCO Holdings Inc is a holding company and operates through its subsidiaries. The company operates across four distinct segments. The first segment is the Steel Segment, which includes the production and sale of steel products. The second segment is the Infrastructure Business, which is further divided into three operations. The Trading Segment comprises trading and natural resource development activities. The Construction Segment involves the planning, designing, and construction of industrial plants, civil engineering projects, and buildings. The Logistics and Others Segment. The third segment is the Secondary Battery Materials Segment, and the fourth segment is the Others Segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.